MA39432A - Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu'inhibiteur de bace - Google Patents

Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu'inhibiteur de bace

Info

Publication number
MA39432A
MA39432A MA039432A MA39432A MA39432A MA 39432 A MA39432 A MA 39432A MA 039432 A MA039432 A MA 039432A MA 39432 A MA39432 A MA 39432A MA 39432 A MA39432 A MA 39432A
Authority
MA
Morocco
Prior art keywords
tetrahydropyrrolo
thiazine
derivative
bace inhibitor
compound
Prior art date
Application number
MA039432A
Other languages
English (en)
Other versions
MA39432B1 (fr
Inventor
David Andrew Coates
Pablo Garcia Losada
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51688001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39432(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39432A publication Critical patent/MA39432A/fr
Publication of MA39432B1 publication Critical patent/MA39432B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Soil Working Implements (AREA)
  • Pyridine Compounds (AREA)

Abstract

<!--startfragment-->la présente invention concerne un composé de formule (i) : qui est cristallin. Le composé de formule (i) est utile dans le traitement de la maladie d'alzheimer (inhibiteur de bace).<!--endfragment-->
MA39432A 2014-09-15 2015-09-08 Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu'inhibiteur de bace MA39432B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382347 2014-09-15
PCT/US2015/048788 WO2016043996A1 (fr) 2014-09-15 2015-09-08 Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu'inhibiteur de bace

Publications (2)

Publication Number Publication Date
MA39432A true MA39432A (fr) 2017-07-26
MA39432B1 MA39432B1 (fr) 2019-07-31

Family

ID=51688001

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39432A MA39432B1 (fr) 2014-09-15 2015-09-08 Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu'inhibiteur de bace

Country Status (40)

Country Link
US (1) US9828390B2 (fr)
EP (1) EP3194408B1 (fr)
JP (1) JP6353977B2 (fr)
KR (1) KR101915419B1 (fr)
CN (1) CN106661054B (fr)
AP (1) AP2017009781A0 (fr)
AR (1) AR101739A1 (fr)
AU (1) AU2015318256B2 (fr)
BR (1) BR112017002586A2 (fr)
CA (1) CA2957043A1 (fr)
CL (1) CL2017000565A1 (fr)
CO (1) CO2017001927A2 (fr)
CR (1) CR20170058A (fr)
CY (1) CY1121709T1 (fr)
DK (1) DK3194408T3 (fr)
DO (1) DOP2017000070A (fr)
EA (1) EA201790238A1 (fr)
EC (1) ECSP17015682A (fr)
ES (1) ES2733326T3 (fr)
HR (1) HRP20190961T1 (fr)
HU (1) HUE044386T2 (fr)
IL (1) IL250350A0 (fr)
LT (1) LT3194408T (fr)
MA (1) MA39432B1 (fr)
MX (1) MX2017003415A (fr)
NZ (1) NZ728660A (fr)
PE (1) PE20170674A1 (fr)
PH (1) PH12017500492A1 (fr)
PL (1) PL3194408T3 (fr)
PT (1) PT3194408T (fr)
RS (1) RS58756B1 (fr)
SG (1) SG11201701637YA (fr)
SI (1) SI3194408T1 (fr)
SV (1) SV2017005392A (fr)
TN (1) TN2017000065A1 (fr)
TR (1) TR201908358T4 (fr)
TW (1) TWI570127B (fr)
UA (1) UA119987C2 (fr)
WO (1) WO2016043996A1 (fr)
ZA (1) ZA201700823B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI574969B (zh) * 2015-01-30 2017-03-21 美國禮來大藥廠 甲苯磺酸鹽
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548774T3 (es) * 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
JO3143B1 (ar) 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Also Published As

Publication number Publication date
ES2733326T3 (es) 2019-11-28
KR20170042678A (ko) 2017-04-19
HRP20190961T1 (hr) 2019-07-26
WO2016043996A1 (fr) 2016-03-24
PH12017500492A1 (en) 2017-08-07
MA39432B1 (fr) 2019-07-31
IL250350A0 (en) 2017-03-30
CL2017000565A1 (es) 2017-11-10
MX2017003415A (es) 2017-06-19
UA119987C2 (uk) 2019-09-10
SG11201701637YA (en) 2017-04-27
CN106661054A (zh) 2017-05-10
EA201790238A1 (ru) 2017-07-31
AP2017009781A0 (en) 2017-03-31
CN106661054B (zh) 2019-09-10
AR101739A1 (es) 2017-01-11
TR201908358T4 (tr) 2019-06-21
SV2017005392A (es) 2018-11-01
SI3194408T1 (sl) 2019-06-28
CY1121709T1 (el) 2020-07-31
EP3194408A1 (fr) 2017-07-26
AU2015318256B2 (en) 2017-12-21
DOP2017000070A (es) 2017-04-16
PT3194408T (pt) 2019-07-12
EP3194408B1 (fr) 2019-04-17
PE20170674A1 (es) 2017-05-22
ZA201700823B (en) 2018-12-19
TN2017000065A1 (en) 2018-07-04
DK3194408T3 (da) 2019-07-15
US20170233410A1 (en) 2017-08-17
JP6353977B2 (ja) 2018-07-04
CA2957043A1 (fr) 2016-03-24
TW201620918A (zh) 2016-06-16
AU2015318256A1 (en) 2017-02-23
ECSP17015682A (es) 2018-03-31
BR112017002586A2 (pt) 2017-12-19
CO2017001927A2 (es) 2017-07-28
LT3194408T (lt) 2019-06-10
KR101915419B1 (ko) 2018-11-05
NZ728660A (en) 2018-06-29
CR20170058A (es) 2017-04-25
JP2017530957A (ja) 2017-10-19
RS58756B1 (sr) 2019-06-28
TWI570127B (zh) 2017-02-11
US9828390B2 (en) 2017-11-28
PL3194408T3 (pl) 2019-09-30
HUE044386T2 (hu) 2019-10-28

Similar Documents

Publication Publication Date Title
MA46337A (fr) Composé de pyridine
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
MA39172A1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
EA201791070A1 (ru) Способы получения ингибиторов ask1
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
MA41607A (fr) Sels d&#39;un inhibiteur de pi3k et procédés de préparation de ces sels
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
MA37940A2 (fr) Nouveaux dérivés bicycliques
EA201491283A1 (ru) Ингибитор регулирующей апоптотические сигналы киназы
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
EA201792021A1 (ru) Ингибитор jak
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d&#39;orexine
EA201691141A1 (ru) Соединения против ccr6
MA40302A1 (fr) Dérivés de carbazole
NZ746906A (en) Oxaborole esters and uses thereof
MA39305A3 (fr) Dérivés d&#39;éthynyle
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MA39432A (fr) Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu&#39;inhibiteur de bace
MA39110A1 (fr) Nouveau composé pour le traitement de l&#39;hypoglycémie grave
MA41975B1 (fr) Derives d&#39;aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d&#39;alzheimer
MA39109A1 (fr) Nouveau composé pour le traitement de l&#39;hypoglycémie grave
MA39108A1 (fr) Nouveau composé pour le traitement de l&#39;hypoglycémie sévère